Short Wave

The global fallout of RFK Jr's vaccine policies

March 4, 2026

Key Takeaways Copied to clipboard!

  • The U.S. policy changes under Robert F. Kennedy, Jr. as HHS Secretary are creating global public health controversies, specifically through an ultimatum to the international vaccine group Gavi regarding the preservative thimerosol, and the funding/support of a controversial hepatitis B vaccine trial in Guinea-Bissau. 
  • The U.S. ultimatum to Gavi demands the removal of thimerosol, a mercury-based preservative deemed safe by major health organizations but opposed by RFK Jr., threatening funding for multi-dose vials essential in lower-income countries. 
  • A U.S.-partially funded hepatitis B vaccine trial in Guinea-Bissau is highly controversial, with critics calling it unethical for withholding immediate, proven post-exposure vaccination from half the newborns to study potential side effects, drawing comparisons to the Tuskegee experiment. 

Segments

RFK Jr. Ultimatum to Gavi
Copied to clipboard!
(00:00:21)
  • Key Takeaway: HHS under RFK Jr. is threatening to withhold funding from Gavi unless the organization removes thimerosol from its vaccines.
  • Summary: Robert F. Kennedy, Jr.’s team threatened to withhold future funding from Gavi unless the organization removes thimerosol from its vaccines. Thimerosol is a preservative made partially from mercury that prevents contamination in multi-dose vaccine vials, which are common in lower-income countries. Gavi stated any changes would follow scientific consensus, but HHS insists funding will be withheld if a phase-out plan is not developed.
Thimerosol Safety and Removal Issues
Copied to clipboard!
(00:05:00)
  • Key Takeaway: Thimerosol, a mercury-based preservative deemed safe since the 1930s, cannot be easily replaced in multi-dose vials used globally, and its removal could lead to vaccine unavailability.
  • Summary: Thimerosol is a well-studied preservative that prevents bacterial or fungal contamination in multi-dose vaccine vials, and the mercury form present leaves the body quickly without known damage. Major health bodies like the WHO and FDA deem it safe, but RFK Jr. has campaigned against it for 20 years. Removing it is difficult in lower-income countries because the required single-dose vials are too expensive.
Controversial Hepatitis B Trial
Copied to clipboard!
(00:08:15)
  • Key Takeaway: A U.S.-partially funded study in Guinea-Bissau tests the safety of the hepatitis B vaccine at birth versus several weeks later, despite high local infection rates and expert condemnation.
  • Summary: Guinea-Bissau has very high rates of hepatitis B, and immediate vaccination at birth is highly effective post-exposure prevention, unlike the current policy of waiting several weeks. The study, funded partly by the U.S., plans to withhold the birth dose from 7,000 newborns to compare side effects, leading the WHO to call the research unethical for exploiting resource scarcity.
Ethical Debate on Vaccine Study
Copied to clipboard!
(00:12:19)
  • Key Takeaway: Critics argue the hepatitis B study is unethical because it fails to ask a valuable question, as the vaccine’s safety is already proven, risking community trust.
  • Summary: Experts argue that since the hepatitis B vaccine is proven safe and effective, the study’s goal of checking for side effects does not constitute a valuable question justifying the risk to unvaccinated infants. Continuing a ‘woefully ineffective’ existing policy while conducting the study is considered cruel and dishonest by some critics. The HHS, however, defended the study as meeting the highest scientific and ethical standards.
Global Public Health Power Shift
Copied to clipboard!
(00:15:20)
  • Key Takeaway: The U.S. is becoming increasingly isolated in global public health due to its stance on vaccines, potentially signaling a shift in global leadership power.
  • Summary: The U.S. is being publicly called out for supporting actions that contradict science and ethics in global health matters. This isolation suggests a potential beginning of a shift in the balance of power regarding who leads the world in public health perspectives. The status of both the Gavi ultimatum and the Guinea-Bissau trial remain unresolved.